NasdaqGM:AXSMPharmaceuticals
Axsome Therapeutics (AXSM): Valuation Perspective Following Paragraph IV Challenge to Symbravo Exclusivity
Axsome Therapeutics (AXSM) just dropped some news that should have every shareholder paying attention. Apotex has officially filed an ANDA with the FDA, complete with a Paragraph IV certification, aiming to launch a generic version of Symbravo. This move signals the possibility of a legal battle over patents, which could determine how long Symbravo remains protected from generic competition. For investors, that means the stakes are high. Any change in exclusivity could reshape revenue streams...